Scholarlink

<p>The reclassification of hemp’s legal status has resulted in a proliferation of retail cannabidiol (CBD) products. Preliminary research is emerging on CBD’s effect on pain, anxiety, depression, and addiction, but CBD is not a cure-all and there is an urgent need for more robust clinical trials. A pharmaceutical CBD product currently exists as an adjunct treatment for epilepsy disorders. However, several patients are experimenting with unregulated retail CBD products as an alternative treatment for a variety of medical conditions. The use of these retail CBD products is not without risks. Given the paucity of medical guidelines, this article provides an update for physicians and other healthcare practitioners on CBD and its potential side effects, drug interactions, and other safety concerns.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

When your patient asks about cannabidiol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Christopher Kudrich,
  • Christina Wiggin

摘要

The reclassification of hemp’s legal status has resulted in a proliferation of retail cannabidiol (CBD) products. Preliminary research is emerging on CBD’s effect on pain, anxiety, depression, and addiction, but CBD is not a cure-all and there is an urgent need for more robust clinical trials. A pharmaceutical CBD product currently exists as an adjunct treatment for epilepsy disorders. However, several patients are experimenting with unregulated retail CBD products as an alternative treatment for a variety of medical conditions. The use of these retail CBD products is not without risks. Given the paucity of medical guidelines, this article provides an update for physicians and other healthcare practitioners on CBD and its potential side effects, drug interactions, and other safety concerns.